GleamWall
中文EN

RPRX Royalty Pharma plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1802768 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.4%
TTM net income YoY-12.1%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR4.0%
Net income 3-yr CAGR53.8%

Margins

Gross margin—
Operating margin57.1%
Net margin25.7%
FCF margin—
EBITDA margin57.3%

Returns

ROE10.1%
ROA3.5%
ROIC (approx.)10.2%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets49.7%
Debt / equity1.26x
Current ratio1.29x
Interest coverage4.02x

Cash quality & payout

Operating cash flow / net income4.41x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$690.10M$674.14M$630.58M$621.99M$609.29M$578.66M$568.25M$593.64M
R&D expense$63.16M$97.85M$39.79M$50.50M$50.50M$300.50M$50.50M$500,000
SG&A expense$150.10M$161.89M$159.49M$164.27M$118.73M$179.77M$110.70M$67.59M
Operating income$410.84M$133.12M$563.04M$388.38M$427.16M$209.80M$534.18M$361.51M
Interest expense$90.49M$93.62M$93.72M$94.17M$79.56M$68.67M$65.26M$65.76M
Pretax income$266.64M$81.49M$468.26M$355.91M$440.21M$92.64M$434.43M$334.35M
Income tax$0$0$0$0$0$0$0$0
Net income$144.68M$17.88M$294.69M$214.21M$284.22M$32.18M$239.35M$208.21M
EBITDA$412.06M$134.41M$564.21M$389.58M$428.43M$211.18M$534.18M$361.51M
EPS (basic)0.320.040.67—0.660.080.55—
EPS (diluted)0.320.040.67—0.660.070.55—
Dividends declared per share0.230.230.230.220.220.220.220.21
Weighted avg. shares (diluted)557.00M556.90M556.84M—559.61M562.30M578.10M—
Balance sheet
Cash & equivalents$513.66M$811.99M$586.39M$618.70M$938.94M$631.91M$1.09B$929.03M
Short-term investments$31.20M$25.00M$21.90M$18.80M$16.10M$13.20M$12.10M$58.20M
Current assets$1.53B$1.76B$1.43B$1.53B$1.85B$1.52B$1.84B$1.80B
Goodwill$923.53M$923.53M$924.63M$924.63M$924.63M$924.63M—$0
Total assets$19.46B$19.82B$19.82B$19.62B$19.35B$18.32B$17.61B$18.22B
Current liabilities$1.18B$630.93M$535.68M$636.21M$530.80M$1.21B$1.18B$1.25B
Short-term debt$996.97M$380.00M$380.00M$380.00M$380.00M$999.44M$998.61M$997.77M
Long-term debt$7.59B$8.58B$8.58B$8.57B$8.57B$7.00B$6.62B$6.61B
Total debt$8.59B$8.96B$8.96B$8.95B$8.95B$8.00B$7.62B$7.61B
Total liabilities$9.67B$10.03B$9.88B$9.91B$9.73B$8.82B$7.82B$7.88B
Shareholders' equity$6.84B$6.83B$6.89B$6.48B$6.40B$6.34B$6.68B$6.95B
Net debt$8.07B$8.15B$8.37B$8.33B$8.01B$7.37B$6.53B$6.68B
Cash flow statement
Operating cash flow$686.08M$728.46M$718.23M$827.15M$702.62M$363.98M$596.08M$742.52M
Investing cash flow-$285.66M-$229.72M-$477.87M-$847.80M-$958.31M-$311.98M$503.92M-$505.59M
Financing cash flow-$698.74M-$273.15M-$272.67M-$299.60M$562.74M-$507.81M-$941.30M-$257.96M
Depreciation & amortization$1.22M$1.29M$1.17M$1.20M$1.28M$1.38M$0$0
Stock-based compensation$105.15M$107.36M$121.99M$125.77M$73.35M$91.04M$515,000$525,000
Share buybacks$86.34M$44.64M$50.10M$80.54M$146.49M$291.57M$708.78M$52.61M

Free plan shows the latest 8 periods; Pro shows all 31 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.